IP Library Granted Patent US 10,046,125
Granted Patent B2
US 10,046,125 · App. 15/343,314 · Granted Aug 14, 2018

Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide

Inventors: Craig R. Tolmie (Stoughton, WI); Jeff Milsap (Cambridge, WI); Jaron M. Acker (Madison, WI)
Assignee: Mallinckrodt Hospital Products IP Limited
A61M16/0051A61M16/0003A61M16/085A61M16/1005A61M16/12A61M16/201G01N27/4163G01N33/0006G01N33/0008G01N33/0037A61M16/16A61M2016/102A61M2016/1035A61M2202/0275A61M2205/18A61M2205/27A61M2205/33A61M2205/502A61M2205/52A61M2205/581A61M2205/583A61M2205/70A61M2205/702
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,046,125
App. No.
15/343,314
Granted
Aug 14, 2018
Kind
B2
Abstract

Systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors. The long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can reduce the amount of times the sensor goes offline. Systems and methods may factor in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.

Claims (47)

1. A method of compensating for nitric oxide sensor drift, comprising;

storing, in memory associated with a nitric oxide delivery device, a calibration schedule;

wherein the nitric oxide delivery device includes a nitric oxide sensor;

in response to a set dosage change, selecting according to the calibration schedule a first zero calibration to be performed after a first interval and a second zero calibration to be performed after a second interval;

performing the first zero calibration after the first interval; and

performing the second zero calibration after the second interval;

wherein the first interval and the second interval are selected according to a magnitude of the set dosage change; and

wherein the first zero calibration and the second zero calibration includes exposing the nitric oxide sensor to a gas having a zero concentration of nitric oxide and adjusting a calibration line according to a detected current output of the nitric oxide sensor during the second zero calibration.

2. The method of claim 1 wherein the second interval is equal to the first interval.

3. The method of claim 1 wherein the second interval is larger than the first interval.

4. The method of claim 3 wherein the second interval is at least twice the first interval.

5. The method of claim 3 further comprising:

performing successive zero calibrations according to successive intervals, wherein the successive intervals increase relative to previous intervals according to the calibration schedule.

6. The method of claim 5 wherein once the successive intervals reach a maximum interval, each successive zero calibration is performed at the maximum interval.

7. The method of claim 6 wherein the maximum interval value is less than or equal to 24 hours.

8. A method of compensating for nitric oxide sensor drift, comprising;

storing in memory associated with a nitric oxide delivery device a calibration schedule and a calibration line;

wherein the nitric oxide delivery device includes a system controller and a nitric oxide sensor;

receiving a set dosage change of nitric oxide to the system controller;

delivering the set dosage of nitric oxide to a breathing circuit from the nitric oxide delivery device;

determining according to the calibration schedule a first zero calibration to be performed at a first interval and a second zero calibration to be performed at a second interval;

wherein the first interval and second interval are selected according to a magnitude of the set dosage change;

performing the first zero calibration after the first interval;

performing the second zero calibration after the second interval; and

wherein the first zero calibration and second zero calibration each include exposing the nitric oxide sensor to a gas having a zero concentration of nitric oxide and adjusting the calibration line.

9. The method of claim 8 wherein the second interval is equal to the first interval.

10. The method of claim 8 wherein the second interval is at least twice the first interval.

11. The method of claim 8 further comprising:

performing successive zero calibrations at successive intervals, wherein the successive intervals increase relative to previous intervals according to the calibration schedule.

12. The method of claim 11 wherein once the successive intervals reach a maximum interval value, each successive zero calibration is performed at the maximum interval value.

13. The method of claim 12 wherein the maximum interval value is less than or equal to 24 hours.

14. A method of compensating for nitric oxide sensor drift, comprising;

storing in a memory associated with a nitric oxide delivery device at least one calibration schedule and a calibration line;

wherein the nitric oxide delivery device is configured to delivery nitric oxide to a breathing circuit;

wherein the nitric oxide delivery device includes a system controller and a nitric oxide sensor;

wherein each calibration schedule indicates that a first zero calibration should be performed after a first interval and a second zero calibration should be performed after a second interval;

receiving a set dosage change to the system controller;

selecting one of the at least one calibration schedules according to a magnitude of the set dosage change;

performing the first zero calibration after the first interval; and

performing the second zero calibration after the second interval;

wherein the first zero calibration and second zero calibration each include exposing the nitric oxide sensor to ambient air having a zero concentration of nitric oxide and adjusting the calibration line according to a measured output of the nitric oxide sensor.

15. The method of claim 14 wherein the second interval is equal to the first interval.

16. The method of claim 14 wherein the second interval is larger than the first interval.

17. The method of claim 16 wherein the second interval is at least twice the first interval.

18. The method of claim 14 further comprising:

performing successive zero calibrations at successive intervals, wherein the successive intervals increase relative to previous intervals according to the calibration schedule.

19. The method of claim 18 wherein once the successive intervals reach a maximum interval value, each successive zero calibration is performed at the maximum interval value.

Assignments (21)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED COMPANY
Reel/Frame 075393/0608 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043601, FRAME 0025 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0233 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043601/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: TOLMIE, CRAIG R.; MILSAP, JEFF; ACKER, JARON M.
To: INO THERAPEUTICS LLC
Reel/Frame 040220/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: MALLINCKRODT PHARMA IP TRADING DAC
To: MALLINCKRODT IP
Reel/Frame 040222/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: MALLINCKRODT CRITICAL CARE FINANCE INC.
To: MALLINCKRODT PHARMA IP TRADING DAC
Reel/Frame 040221/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: THERAKOS, INC.
To: MALLINCKRODT CRITICAL CARE FINANCE INC.
Reel/Frame 040220/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: INO THERAPEUTICS LLC
To: THERAKOS, INC.
Reel/Frame 040220/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: MALLINCKRODT IP
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 040222/0479 →
Continuity (4)
Continuation 15010999 · Jan 29, 2016
Continuation 14626409 · Feb 19, 2015
Provisional Application 61941725 · Feb 19, 2014
Related Publication 20170074844A1 · Mar 16, 2017